Ambivalence about the selection of cardiovascular risk stratification tools: Evidence in a type 1 diabetes population

Diabetes Metab Syndr. 2019 May-Jun;13(3):2322-2327. doi: 10.1016/j.dsx.2019.05.024. Epub 2019 May 24.

Abstract

Background: Cardiovascular disease (CVD) is one of the leading causes of death among people with diabetes, however, despite the increasing incidence of CVD, there are few tools for evaluating Cardiovascular Risk (CVR) in the population of patients with Type 1 Diabetes (T1D), with the existing ones diverging in the stratification of risk and in the suggestions for therapeutic conduct.

Methods: A cross-sectional study was carried out with 104 participants diagnosed with T1D, aged 18-40, attending specialized services. The Steno Type 1 Risk Engine and the Cardiovascular Risk Stratification Calculator (CRSC) were used to assess the risk of a cardiovascular event over a 10-year period.

Findings: Of the total sample selected, 62% were female, with a median age of 32 years (IQ 24; 43). There was a large difference between the stratification of CVR between the calculators, and 65.82% of the patients classified as low risk for CVD according to the Steno were identified as intermediate (30, 38.00%) and high risk (35.44%) by the CRSC. The analysis also highlighted a great difference in eligibility for statin use according to the risk stratification of the tools.

Conclusion: The CRSC and Steno tools evaluated and stratified the CVR of the same population with T1D, with there being divergence of the results. It was found that the CRSC tool classified the majority of the sample as high risk. Due to this result, the eligibility to use statins, which is one of the applications of these tools, showed great differences, with the Steno tool presenting less aggressive provisions regarding the prescription of statins in patients with type 1 DM.

MeSH terms

  • Adolescent
  • Adult
  • Biomarkers / analysis
  • Brazil / epidemiology
  • Cardiovascular Diseases / diagnosis*
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / etiology
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 1 / complications*
  • Diabetes Mellitus, Type 1 / epidemiology
  • Female
  • Follow-Up Studies
  • Guideline Adherence*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Male
  • Practice Guidelines as Topic / standards*
  • Prognosis
  • Risk Assessment / methods*
  • Risk Factors
  • Young Adult

Substances

  • Biomarkers
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors